Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls (STTR)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Albany Medical College.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Albany Medical College
Collaborator:
Information provided by:
Albany Medical College
ClinicalTrials.gov Identifier:
NCT01379716
First received: June 22, 2011
Last updated: NA
Last verified: December 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Postherpetic Neuralgia is a painful nerve condition that can occur when nerve fibers are damaged following an outbreak of shingles.
The purpose of this study is to identify and study abnormalities in the nerves and cells in the of patients with postherpetic Neuralgia (PHN) and characterize changes that could be responsible for causing nerve pain. This data will be compared to the tissue of healthy volunteers. Our goal is that this information will lead to the development of better treatment options for people with painful nerve conditions.
| Condition | Intervention | Phase |
|---|---|---|
|
Postherpetic Neuralgia Healthy Age/Gender Matched Volunteers |
Other: skin biopsy |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia (PHN) and Age and Gender-Matched Normal Controls |
Resource links provided by NLM:
Further study details as provided by Albany Medical College:
Primary Outcome Measures:
- use of genetic data to enhance the search for targeted therapeutic approaches to chronic pain management [ Time Frame: One year ] [ Designated as safety issue: No ]The skin biopsies will be used to identify the site of expression of selected makers in skin, including nerve fibers and skin substructures in patients with PHN and age and gender-atched normal controls.
| Estimated Enrollment: | 10 |
| Study Start Date: | January 2011 |
| Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Other: skin biopsy
Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
Eligibility| Ages Eligible for Study: | 50 Years to 95 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Group 1: 5 Caucasian males >50 years of age with PHN of greater than 6 months duration since rash healed and clinically meaningful pain (Visual Analog Scale (VAS) >40mm at Baseline) Group 2: 5 Caucasian males >50 years of age, non-diabetic with no nervous system disease (healthy control groups)
Exclusion Criteria:
- History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator
- Allergy to lidocaine
- Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study
- History of slow-healing diabetic foot ulcers
- HgA1c >11% within the last three months
- Active cancer within the previous two years, except treated basal cell carcinoma of the skin
- Co-morbidities that can produce neuropathy
- Subjects taking sodium channel blockers within one week of study treatment and throughout the study
- Subjects taking any other experimental drugs within 30 days prior to enrollment
- Application of lidocaine patch to either foot or to PHN site within two weeks of enrollment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01379716
Contacts
| Contact: Margaret Czerwinski, BSN, RN | (518)262-0034 | czerwim@mail.amc.edu |
| Contact: Katy Regan, BS | (518)262-5938 | regank@mail.amc.edu |
Locations
| United States, New York | |
| Albany Medical College | Recruiting |
| Albany, New York, United States, 12208 | |
Sponsors and Collaborators
Albany Medical College
Investigators
| Principal Investigator: | James P. Wymer, MD | Albany Medical College |
More Information
No publications provided
| Responsible Party: | Charles Argoff, MD, The Neurosciences Institute |
| ClinicalTrials.gov Identifier: | NCT01379716 History of Changes |
| Other Study ID Numbers: | INT/AMC-001 |
| Study First Received: | June 22, 2011 |
| Last Updated: | June 22, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Neuralgia Neuralgia, Postherpetic Pain Neurologic Manifestations |
Nervous System Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013